SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Tom John

Tom John

Peter MacCallum Cancer Centre, Melbourne

Associate Prof. Tom John is a thoracic medical oncologist and Deputy Director of Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia. He has led and contributed to practice-changing trials in EGFR-mutant non-small cell lung cancer, including the AURA, FLAURA and ADAURA osimertinib programmes and circulating tumour DNA / molecular residual disease research, alongside translational work in mesothelioma. He is an Associate Editor of the Journal of Thoracic Oncology, serves on the ESMO lung tumour faculty, chairs the Scientific Committee of the Thoracic Oncology Group of Australasia, and is a frequent speaker at major international congresses.

Connect

Tom John

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates